2. Disease Areas
  3. Metabolic or Endocrine Disease
  4. Mineral Metabolism
  5. Iron Deficiency Anemia

Iron Deficiency Anemia

Iron deficiency anemia is the most common form of anemia worldwide, resulting from insufficient iron stores that impair hemoglobin synthesis and reduce the production of healthy red blood cells necessary for oxygen transport. It commonly affects women of childbearing age and infants due to increased iron demands or inadequate dietary intake, and can also arise from chronic blood loss, malabsorption, or poor iron absorption. The condition progresses through stages, with early signs including depleted bone marrow iron stores while hemoglobin and serum iron remain normal. As it advances, symptoms such as fatigue, weakness, pallor, shortness of breath, and lightheadedness develop due to reduced oxygen delivery to tissues. Diagnosis is confirmed by blood tests showing low serum iron, ferritin, and transferrin saturation, along with elevated total iron-binding capacity. Treatment involves addressing underlying causes—such as bleeding or dietary deficiencies—and restoring iron levels through oral supplements or dietary modifications. Without intervention, iron deficiency anemia can impair growth and development in children and lead to long-term complications.

Iron Deficiency Anemia (3):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W581798
    Iron(II) sulfate hydrate 17375-41-6
    Iron(II) sulfate hydrate is an iron(II) salt with oral activity, acting as an iron supplier, and is easily oxidized to iron(III) in water. Iron(II) sulfate hydrate induces apoptotic morphological changes in cancer cells, and promotes dose‑dependent iron accumulation in rats. Iron(II) sulfate hydrate can be used in studies of leukemia, breast cancer, iron deficiency, anemia, and restless legs syndrome.
    Iron(II) sulfate hydrate
  • HY-P991855
    RKER-216
    RKER-216 is a human monoclonal IgG antibody inhibitor targeting ALK2 with a KD of 58.7 pM. RKER-216 reduces hepcidin transcription in Hep3B.RKER-216 competes with BMP ligands for binding to the extracellular domain of ALK2, thereby inhibiting BMP-SMAD signal. RKER-216 mobilizes tissue iron effectively in inflammatory conditions. RKER-216 improves microcytic anemia in a dose-dependent manner by inhibiting SMAD signaling to reduce hepcidin and promote iron absorption and utilization in vivo. RKER-216 can be used for research on anemia of inflammation.
    RKER-216
  • HY-W698271
    Ferrous lactate trihydrate 6047-24-1
    Ferrous lactate trihydrate is a type of iron supplement. Ferrous lactate trihydrate promotes the production of hemoglobin by providing available ferrous ions (Fe²⁺). Ferrous lactate trihydrate can be used in studies on iron-deficiency anemia.
    Ferrous lactate trihydrate